Molecular characteristics in lung cancer are associated with carcinogenesis, response to targeted therapies, and prognosis.
With concurrent oncogene mutations being reported more often, the adjust-ment of treatment based on the driver gene
mutations would improve therapy. We proposed to investigate the distribution of concurrent oncogene mutations in stage Ib
lung adenocarcinoma in a Chinese population and find out the correlation between survival outcome and the most frequently mutated genes in EGFR and KRAS in Chinese population. Simultaneously, we tried to validate the Sequenom method by real
time fluoresce qualification reverse transcription polymerase chain reaction (RT-PCR) in oncogene detection.
Medicine, Volume 93, Number 29, December 2014
Epidermal growth factor receptor (EGFR) mutationanalysis is becoming a routine clinical practice forlung adenocarcinoma
patients. Most patients with lung cancerare diagnosed at an advanced stage of the disease andare not suitable for surgical
therapy. In many cases, cytologicspecimens may be the only tissue available for diagnosticand molecular testing. Therefore, it
is important todetermine what condition the cytologic specimens shouldbe in for adequately analyzing EGFR mutation status.
J Cancer Res Clin Oncol, 15 August 2014. DOI 10.1007/s00432-014-1807-z
The PIK3CA gene mutation was found to associate with prognosis and might affect molecular targeted therapy in esophageal carcinoma (EC). The aim of this study is to compare different methods for analyzing the PIK3CA gene mutation in EC.
Diagnostic Pathology 2014, 9:153
Epidermal growth factor receptor (EGFR) mutations in cerebrospinal ﬂuid (CSF) might be useful predictive markers for EGFR
tyrosine kinase inhibitor treatment of intracranial metastatic tumors. In this retrospective study, amplification refractory
mutation system (ARMS)-PCR assays were used to investigate the EGFR gene status in 30 lung adenocarcinoma patients with brain metastases.
The Journal of Molecular Diagnostics, Vol.16, No.5, September 2014
The detection of somatic epidermal growth factor receptor (EGFR) mutations is valuable when an appropriate therapy, either
EGFR-tyrosine kinase inhibitor (TKI) therapy or chemotherapy, for patients with advanced non-small cell lung cancer (NSCLC)
needs to be selected. Although it is well-understood that EGFR mutation detection is significant for the decision-making
regarding treatment, no consensus on the methodology that should be the most preferebale for detecting mutations in
clinical practice has been reached.
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 34: 464-474, 2014
Somatic mutations in the gene of epidermal growth factor receptor (EGFR) and KRAS are associated with sensitivity and
resistance to the kinase inhibitors in targeted therapy. Detection of EGFR and KRAS mutations is now a necessary procedure
for treatment of non-small-cell lung cancer (NSCLC) before using EGFR tyrosine kinase inhibitors (EGFR-TKI).
Bio Med Research International, Volume 2014, Article ID 407537, 7 pages